News & Media Press releases & statements Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Apply filter Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Apply filter Year All Years 2023 2022 2021 2020 2019 2018 2017 2016 2015 Category All categories Type - Statement - Press release Topic - Corporate and finance - Global health - Partnerships Research area - COVID-19 - Ebola - RSV - Seasonal influenza Uncategorized Keywords Apply filter Advanced Search Search Search Headlines Only Type All Statement Press release Topic All Corporate and finance Global health Partnerships Research area All COVID-19 Ebola RSV Seasonal influenza From To Asset Types Photos Video Audio Documents Events Standard Jan 27, 2023 StatementCOVID-19 Novavax Announces Plan to Deliver Updated Protein-based Vaccine Consistent with FDA Recommendations for 2023/2024 Vaccination Season at VRBPAC Meeting Download Jan 18, 2023 COVID-19 Novavax Nuvaxovid COVID-19 Vaccine Approved in South Korea as an Adult Booster Download Dec 30, 2022 COVID-19Seasonal influenza Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates Download Dec 16, 2022 StatementGlobal healthCOVID-19 German Health Authority Expands Recommendation for Use of Novavax COVID-19 Vaccine as a Booster Download Dec 7, 2022 COVID-19 Novavax Nuvaxovid COVID-19 Vaccine Approved in Canada for Use as a Primary Series in Adolescents Download Nov 29, 2022 COVID-19 World Health Organization Updates Emergency Use Listing for Novavax Nuvaxovid COVID-19 Vaccine as a Primary Series in Adolescents and as a Booster in Adults Download Nov 23, 2022 StatementCOVID-19 Termination of COVID-19 Vaccine Purchase Agreement with Gavi Download Nov 18, 2022 COVID-19 Novavax Nuvaxovid COVID-19 Vaccine Receives Expanded Authorization in Canada as a Booster in Adults Download Nov 9, 2022 COVID-19 Novavax Nuvaxovid™ COVID-19 Vaccine▼ Authorized in the United Kingdom for Use as a Booster in Adults Download Nov 8, 2022 COVID-19 Novavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster Download Oct 20, 2022 COVID-19Seasonal influenza Novavax Showcases Data from Expanding Vaccine Portfolio at IDWeek 2022 Download Oct 19, 2022 StatementCOVID-19 U.S. Centers for Disease Control and Prevention Recommends Novavax COVID-19 Vaccine, Adjuvanted as a Booster in Adults Download Oct 19, 2022 COVID-19 U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster for Adults Download Oct 13, 2022 COVID-19Seasonal influenza Novavax COVID-19-Influenza Combination Vaccine Candidate Induced Antibody and T-Cell Responses Against SARS-CoV-2 and Homologous and Heterologous Influenza Strains Download Oct 12, 2022 COVID-19 Novavax Prototype COVID-19 Vaccine Data Support Homologous and Heterologous Boosting and Suggest Benefit Against Variants Download Oct 10, 2022 COVID-19Seasonal influenza Novavax to Share New Data from Growing Vaccine Portfolio at World Vaccine Congress Europe 2022 Download Sep 27, 2022 COVID-19 Novavax Makes One Million Doses of Nuvaxovid™ Available for Use in the United Kingdom Download Sep 16, 2022 COVID-19 Novavax Nuvaxovid™ COVID-19 Vaccine Receives Expanded Emergency Use Authorization in Taiwan for Use in Adolescents Aged 12 Through 17 Download Sep 16, 2022 COVID-19 Novavax Nuvaxovid™ COVID-19 Vaccine Now Available in Israel for Individuals Aged 12 and Older Download Sep 13, 2022 COVID-19 Novavax and Serum Institute of India Announce Full Product Registration in South Africa of Novavax COVID-19 Vaccine as a Primary Series for Adults Aged 18 and Older Download Sep 12, 2022 COVID-19 Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the European Union for Use as a Booster for Adults Aged 18 and Older Download Sep 2, 2022 COVID-19 Swissmedic Authorizes Novavax Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 Through 17 and as a Booster in Adults Aged 18 and Older Download Sep 2, 2022 StatementCOVID-19 World Health Organization Approves SK bioscience as a Supplier of Novavax Nuvaxovid™ COVID-19 Vaccine Download Sep 1, 2022 COVID-19 Novavax Nuvaxovid™ COVID-19 Vaccine Recommended by CHMP for Expanded Conditional Marketing Authorization in the European Union as a Booster for Adults Aged 18 and Older Download Aug 26, 2022 COVID-19 Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the United Kingdom for Use in Adolescents Aged 12 Through 17 Download Aug 22, 2022 StatementCOVID-19 U.S. Centers for Disease Control and Prevention Expands Recommendation for Novavax COVID-19 Vaccine, Adjuvanted to Adolescents Aged 12 Through 17 Download Aug 19, 2022 COVID-19 U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Adolescents Aged 12 Through 17 Download Aug 18, 2022 COVID-19 Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand for Adolescents Aged 12 Through 17 Download Aug 17, 2022 COVID-19 Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand as a First and Second Booster for Adults Download Aug 15, 2022 COVID-19 Novavax Submits Application to the U.S. FDA for Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster in Adults Aged 18 and Older Download Aug 12, 2022 COVID-19 Novavax Nuvaxovid™ COVID-19 Vaccine Approved in South Korea for Use in Adolescents Aged 12 Through 17 Download Aug 10, 2022 StatementCOVID-19 Novavax and Serum Institute of India Receive Expanded Emergency Use Authorization for Novavax’ COVID-19 Vaccine in Thailand in Adolescents Aged 12 Through 17 Download Aug 4, 2022 COVID-19 Novavax Announces Initiation of Phase 2b/3 Hummingbird™ Global Clinical Trial for the Novavax COVID-19 Vaccine in Children Aged Six Months Through 11 Years Download Aug 1, 2022 StatementCOVID-19 Novavax Statement on U.S. Vaccinations with the Novavax COVID-19 Vaccine, Adjuvanted Underway Download Jul 26, 2022 COVID-19 Novavax Announces Expanded Approval of Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 through 17 in Japan Download Jul 26, 2022 COVID-19 Novavax Nuvaxovid™ COVID-19 Vaccine Granted Provisional Registration in Australia for Use in Adolescents Aged 12 Through 17 Download Jul 22, 2022 StatementCOVID-19 Novavax Statement on U.S. Availability of the Novavax COVID-19 Vaccine, Adjuvanted Download Jul 19, 2022 StatementCOVID-19 U.S. Centers for Disease Control and Prevention Endorses Advisory Committee on Immunization Practices’ Recommendation for Novavax COVID-19 Vaccine, Adjuvanted Download Jul 19, 2022 COVID-19 U.S. CDC Advisory Committee Unanimously Recommends Novavax COVID-19 Vaccine, Adjuvanted as a Primary Series for Individuals Aged 18 and Older Download Jul 19, 2022 COVID-19 Novavax Announces Expanded Agreement with SK bioscience to Manufacture COVID-19 Vaccine Containing Omicron Variant and Manufacture the Novavax COVID-19 Vaccine in Prefilled Syringes Download Jul 15, 2022 StatementCOVID-19 Novavax COVID-19 Vaccine to be Reviewed at U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices Meeting on July 19, 2022 Download Jul 14, 2022 StatementCOVID-19 Novavax Statement on European Medicines Agency Nuvaxovid™ Label Update Related to Allergic Reaction Download Jul 13, 2022 COVID-19 U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Individuals Aged 18 and Over Download Jul 11, 2022 COVID-19 U.S. Government Secures 3.2 Million Doses of Novavax COVID-19 Vaccine Download Jul 7, 2022 StatementGlobal healthCOVID-19 Novavax Files in Switzerland for Expanded Conditional Marketing Authorization of Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 Through 17 and as a Booster in Individuals Aged 18 and Over Download Jul 7, 2022 StatementGlobal healthCOVID-19 European Medicines Agency Approves SK bioscience as a Supplier of Novavax Nuvaxovid™ COVID-19 Vaccine Download Jul 5, 2022 COVID-19 Novavax Nuvaxovid™ COVID-19 Vaccine Conditionally Authorized in the European Union for Adolescents Aged 12 Through 17 Download Jul 1, 2022 StatementGlobal healthCOVID-19 Novavax Statement on Prototype Vaccine’s Broad Immune Responses and Accelerated Focus on Omicron BA.4/5 as Recommended by the FDA Download Jun 28, 2022 COVID-19 Novavax COVID-19 Data Presented at FDA VRBPAC Meeting Demonstrates Broad Antibody Responses to Both Prototype and Omicron-Specific Variants Download Jun 28, 2022 StatementGlobal healthCOVID-19 Novavax to Participate in Vaccines and Related Biological Products Advisory Committee Review of COVID-19 Vaccines Strain Composition Download Jun 23, 2022 COVID-19 Novavax' Nuvaxovid™ COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan for Use in Individuals Aged 18 and Over Download Jun 23, 2022 COVID-19 Novavax COVID-19 Vaccine Nuvaxovid™ Recommended for Expanded Conditional Marketing Authorization in the European Union by CHMP for Adolescents Aged 12 Through 17 Download Jun 23, 2022 StatementGlobal healthCOVID-19 Novavax Files Supplement to a New Drug Submission in Canada for Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 Through 17 Download Jun 17, 2022 StatementCOVID-19Seasonal influenza Novavax to Showcase Innovative Vaccine Data at Communicable Diseases & Immunisation Conference 2022 Download Jun 13, 2022 COVID-19 Novavax COVID-19 Vaccine Nuvaxovid™ Provisionally Registered in Australia as a Booster in Individuals Aged 18 and Over Download Jun 7, 2022 COVID-19 FDA Advisory Committee Recommends Emergency Use Authorization of Novavax COVID-19 Vaccine for People Aged 18 Years and Older Download Jun 7, 2022 Corporate and financeCOVID-19 Novavax Statement on Stock Trading Halt; FDA Advisory Committee to Review Novavax’ COVID-19 Vaccine Download Jun 3, 2022 StatementCOVID-19 Novavax Statement on US FDA Briefing Document Related to Myocarditis/Pericarditis Download Jun 2, 2022 StatementGlobal healthCOVID-19 Novavax Files in the United Kingdom for Expanded Conditional Marketing Authorization of COVID-19 Vaccination as a Booster in Adults Aged 18 and Over Download May 31, 2022 StatementGlobal healthCOVID-19 Novavax Initiates Phase 3 Trial of its COVID-19 Omicron Strain Vaccine as a Booster Download May 26, 2022 StatementGlobal healthCOVID-19 FDA Confirms Vaccines and Related Biological Products Advisory Committee Review of Novavax’ COVID-19 Vaccine on June 7, 2022 Download May 25, 2022 StatementGlobal healthCOVID-19 Novavax Announces Participation in Oxford University Com-COV3 Booster Trial of COVID-19 Vaccines in Adolescents Aged 12 Through 15 Download May 20, 2022 StatementGlobal healthCOVID-19 Novavax Files in the European Union for Expanded Conditional Marketing Authorization of COVID-19 Vaccine as a Booster in Individuals Aged 18 and Over Download May 13, 2022 StatementCOVID-19 Novavax Files for Emergency Use Authorization of COVID-19 Vaccine in Taiwan Download May 6, 2022 StatementCOVID-19 Novavax Submits Variations to Expand Australian and New Zealand Provisional Approval of Nuvaxovid™ COVID-19 Vaccine to Adolescents aged 12 Through 17 Years Download May 6, 2022 StatementCOVID-19 Novavax’ COVID-19 Vaccine Nuvaxovid™ Arrives in Singapore Download Apr 29, 2022 COVID-19 FDA Announces Vaccines and Related Biological Products Advisory Committee Review of Novavax' COVID-19 Vaccine Download Apr 22, 2022 COVID-19 Novavax Announces Initiation of COVID-19 Vaccine Booster Study in Adolescents in Phase 3 PREVENT-19 Trial Download Apr 20, 2022 COVID-19 Initial Results from Novavax' COVID-19-Influenza Vaccine Trial are First to Show Feasibility of Combination Vaccine Download Apr 19, 2022 COVID-19 Novavax Announces Approval of Nuvaxovid™ COVID-19 Vaccine for Primary and Booster Immunization in Japan Download Apr 18, 2022 COVID-19 Novavax Grows Presence at World Vaccine Congress and 32nd European Congress of Clinical Microbiology & Infectious Diseases Download Apr 13, 2022 COVID-19 Swissmedic Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine Download Apr 8, 2022 COVID-19 Novavax and Serum Institute of India Receive Emergency Use Authorization for Novavax' COVID-19 Vaccine in Thailand Download Mar 31, 2022 COVID-19 Novavax Submits Request to Expand Conditional Marketing Authorization of COVID-19 Vaccine in the European Union to Adolescents (Ages 12-17) Download Mar 25, 2022 COVID-19 Novavax Announces Participation in Two Booster Studies Using its COVID-19 Vaccine Download Mar 22, 2022 COVID-19 Novavax and Serum Institute of India Announce First Emergency Use Authorization of Novavax' COVID-19 Vaccine in Adolescents ≥12 to <18 in India Download Feb 28, 2022 COVID-19 Novavax Announces Extended Durability of Protection Against Infection and Disease in United Kingdom COVID-19 Vaccine Phase 3 Clinical Trial Download Feb 23, 2022 COVID-19 Novavax Announces Shipments of its COVID-19 Vaccine to European Union Member States Download Feb 17, 2022 COVID-19 Health Canada Authorizes Novavax COVID-19 Vaccine Download Feb 14, 2022 Press releaseCOVID-19 Singapore Health Sciences Authority Issues Interim Authorization for Novavax COVID-19 Vaccine Download Feb 14, 2022 COVID-19 Novavax Files for Conditional Marketing Authorization of COVID-19 Vaccine in Switzerland Download Feb 10, 2022 COVID-19 Novavax Announces Positive Results of COVID-19 Vaccine in Pediatric Population of PREVENT-19 Phase 3 Clinical Trial Download Feb 3, 2022 COVID-19 New Zealand's Medsafe Grants Provisional Approval for Novavax' COVID-19 Vaccine Download Feb 3, 2022 COVID-19 Medicines and Healthcare Products Regulatory Agency Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine in Great Britain* Download Jan 31, 2022 COVID-19 Novavax Submits Request to the U.S. FDA for Emergency Use Authorization of COVID-19 Vaccine Download Jan 28, 2022 COVID-19 Novavax and Israel Announce Advance Purchase Agreement for Supply of COVID-19 Vaccine Download Jan 19, 2022 COVID-19 Australia Therapeutic Goods Administration (TGA) Grants Provisional Registration for Novavax COVID-19 Vaccine Download Jan 12, 2022 COVID-19 South Korea Ministry of Food and Drug Safety Approves Novavax COVID-19 Vaccine Download Jan 10, 2022 COVID-19 Novavax and Serum Institute of India File for Emergency Use Authorization of Novavax' COVID-19 Vaccine in South Africa Download Dec 31, 2021 COVID-19 Novavax Submits Final Data Packages to U.S. FDA as Prerequisite to Emergency Use Authorization Application Request for COVID-19 Vaccine Download Dec 28, 2021 COVID-19 Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in India Download Dec 23, 2021 COVID-19 Novavax and SK bioscience Expand Manufacturing Agreement Download Dec 22, 2021 COVID-19 Novavax Announces Initial Omicron Cross-Reactivity Data from COVID-19 Vaccine Booster and Adolescent Studies Download Dec 21, 2021 COVID-19 Novavax Announces Initiation of PREVENT-19 COVID-19 Vaccine Phase 3 Trial Booster Study Download Dec 20, 2021 COVID-19 World Health Organization Grants Second Emergency Use Listing for Novavax COVID-19 Vaccine Download Dec 20, 2021 COVID-19 European Commission Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine Download Dec 20, 2021 COVID-19 Novavax Receives Positive European Medicines Agency Recommendation for Conditional Marketing Authorization of its COVID-19 Vaccine Download Dec 17, 2021 COVID-19 Novavax and Serum Institute of India Announce World Health Organization Grants Emergency Use Listing for NVX-CoV2373 COVID-19 Vaccine Download Dec 15, 2021 COVID-19 Novavax Announces Submission of New Drug Application in Japan for Approval of COVID-19 Vaccine Download Dec 15, 2021 StatementCOVID-19 Novavax Statement on PREVENT-19 Phase 3 Clinical Trial Results Publication in the New England Journal of Medicine Download Show 5102550100 per page«12»